UroGen Pharma URGN Business Segments — Other Research And Development Expense

Similar metrics at other companies

ALMSSingle Reportable — Other Research And Development Expense

$2.37M+3.2%

DWTXSingle Reportable — Other Research And Development Expense

$585.61K+33.4%

CLDXSingle Reportable — Other Research And Development Expense

$6.14M+71.1%

LNTHReportable — Other Research And Development Expense

$29.73M-18.7%

SLDBExternal Research And Development Other — Other Research And Development Expense

$1.98M-36.4%

TGTXOther Research And Development Expense

$87.27M+218%

FAQ

What is UroGen Pharma's business segments — other research and development expense?

UroGen Pharma (URGN) reported business segments — other research and development expense of $258K in Q2 2026.

What does business segments — other research and development expense mean?

This metric includes miscellaneous research and development costs that do not fall under primary labor or clinical trial categories, such as supplies, equipment maintenance, or specialized consulting. It provides visibility into the secondary operational expenses necessary to support the broader R&D ecosystem. Tracking this helps identify fluctuations in the non-labor costs of maintaining a clinical-stage pipeline.